# Pegaferon and Ribavirin for Hepatitis C

> **NCT01137383** · PHASE3 · COMPLETED · sponsor: **Tehran University of Medical Sciences** · enrollment: 108 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Pegaferon (pegylated interferon alpha 2a) + ribavirin

## Key facts

- **NCT ID:** NCT01137383
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-12
- **Final completion:** 2010-02
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2010-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137383, "Pegaferon and Ribavirin for Hepatitis C". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01137383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*